Comments Regarding Identification, Assessment, and Control of Nitrosamine Drug Substance-Related Impurities in Human Drug Products Share page: Docket Number: FDA-2023-N-1585-0001 Download Document Issues: OTC Medicines Other Issues Quality Related Posts Press Releases and Statements West Virginia Expands Access to OTC Cold & Allergy Medications Containing PSE Mar 6, 2024 Press Releases and Statements CHPA Statement on Valisure Citizen Petition Mar 6, 2024 Summary of State Sales Tax Jun 1, 2018